drugset / Trial / NCT00254293

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293

Phase 1/2 Completed 87 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.

Timeline

Start
2006-01
Primary completion
2007-05
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified 75 mg Intravenous
Comparator Abatacept Other / unclassified 125 mg Intravenous
Comparator Abatacept Other / unclassified 200 mg Intravenous

Indications